Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Xoma Corp (XOMA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 269,841
  • Shares Outstanding, K 8,140
  • Annual Sales, $ 5,560 K
  • Annual Income, $ -53,530 K
  • 36-Month Beta 3.17
  • Price/Sales 5.01
  • Price/Cash Flow N/A
  • Price/Book 61.06

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.15 +7.80%
on 01/09/18
37.25 -9.85%
on 12/28/17
+1.89 (+5.96%)
since 12/19/17
3-Month
21.61 +55.39%
on 10/26/17
37.25 -9.85%
on 12/28/17
+10.31 (+44.31%)
since 10/19/17
52-Week
3.96 +747.98%
on 02/10/17
37.25 -9.85%
on 12/28/17
+28.83 (+606.95%)
since 01/19/17

Most Recent Stories

More News
Novo Nordisk's (NVO) Hits 52-Week High: What's Driving It?

Regulatory approvals of some key pipeline candidates along with the strong performance of products like Victoza have contributed to a rally in Novo Nordisk's (NVO) shares.

XOMA : 33.58 (+1.30%)
SCMP : 17.95 (unch)
NVO : 57.79 (+2.27%)
EXEL : 28.00 (+0.50%)
Recent Analysis Shows XOMA, Washington Real Estate Investment Trust, TransMontaigne Partners, Triumph, Hemispherx BioPharma, and Virtus Investment Partners Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of XOMA Corporation (NASDAQ:XOMA),...

XOMA : 33.58 (+1.30%)
VRTS : 131.05 (+1.08%)
HEB : 0.49 (-7.55%)
TLP : 41.97 (+1.65%)
WRE : 28.84 (+0.87%)
TBK : 36.00 (+3.23%)
3 Pharma and Biotech Stocks to Watch Out for in 2018

Here is a look at three pharma and biotech stocks including Alkermes (ALKS) that look well-positioned for 2018.

XOMA : 33.58 (+1.30%)
NVS : 86.94 (+0.61%)
ALKS : 57.03 (+1.62%)
BIIB : 342.41 (-0.59%)
EIGR : 8.85 (-0.56%)
Aradigm's Bronchiectasis Candidate Has Negative FDA Vote

The FDA panel votes against the approval of Aradigm's (ARDM) Linhaliq for treatment of non-cystic fibrosis bronchiectasis. A response from the regulatory agency is expected on Jan 26, 2018.

XOMA : 33.58 (+1.30%)
ARDM : 2.29 (+8.02%)
SCMP : 17.95 (unch)
EXEL : 28.00 (+0.50%)
Perrigo (PRGO) Hits 52-Week High: What's Driving the Stock?

We look at the factors that drive the share price of Perrigo to a 52-week high.

XOMA : 33.58 (+1.30%)
SCMP : 17.95 (unch)
EXEL : 28.00 (+0.50%)
PRGO : 91.88 (+0.21%)
Vertex's Cystic Fibrosis Drug Ok'd for Pediatric Use in EU

Vertex (VRTX) receives extension of the marketing application for Orkambi to include use in children with CF who have two copies of the F508del mutation from European Commission.

XOMA : 33.58 (+1.30%)
VRTX : 157.97 (+0.50%)
EXEL : 28.00 (+0.50%)
PRTK : 15.93 (+0.47%)
Why is Novo Nordisk Stock Up More Than 50% in Past Year?

We take a look at the factors that led to the rise in Novo Nordisk's (NVO) share price in the past year.

XOMA : 33.58 (+1.30%)
SCMP : 17.95 (unch)
NVO : 57.79 (+2.27%)
EXEL : 28.00 (+0.50%)
Adamas (ADMS) Launches Dyskinesia Drug in the US, Stock Up

Adamas (ADMS) shares climb on the commercial launch of Gocovri in the United States for treating dyskinesia in patients with Parkinson's disease. This is the first FDA approved drug for the ailment.

XOMA : 33.58 (+1.30%)
SCMP : 17.95 (unch)
ADMS : 38.19 (+2.14%)
EXEL : 28.00 (+0.50%)
Acorda's Shares Down on Disappointing Ampyra View for 2018

Acorda (ACOR) announces preliminary sales numbers of its key multiple sclerosis drug, Ampyra, for Q4. The company's net sales expectations are higher year over year.

XOMA : 33.58 (+1.30%)
SCMP : 17.95 (unch)
EXEL : 28.00 (+0.50%)
ACOR : 27.20 (+8.80%)
Novo Nordisk Confirms Bid for Ablynx But Faces Rejection

Novo Nordisk (NVO) confirmed its revised offer made on Dec 22, to acquire Ablynx NV for $3.1 billion.

XOMA : 33.58 (+1.30%)
SCMP : 17.95 (unch)
NVO : 57.79 (+2.27%)
EXEL : 28.00 (+0.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1' with potential...

See More

Key Turning Points

2nd Resistance Point 35.11
1st Resistance Point 34.34
Last Price 33.58
1st Support Level 32.28
2nd Support Level 30.99

See More

52-Week High 37.25
Last Price 33.58
Fibonacci 61.8% 24.53
Fibonacci 50% 20.60
Fibonacci 38.2% 16.68
52-Week Low 3.96

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.